ArticleScientific reports2025
The role of urinary biomarkers in the diagnosis of acute kidney injury in patients with liver cirrhosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications 2026.Clinical and molecular hepatology · 2026Article
- Clinical prediction of the mortality for acute kidney injury in decompensated cirrhosis.Scientific reports · 2026Article
- Clinical diagnosis and biomarkers of acute kidney injury in liver cirrhosis: a systematic review.Therapeutic advances in gastroenterology · 2026Review
- Acute Kidney Injury in Patients with Liver Cirrhosis: From Past to Present Definition and Diagnosis.Life (Basel, Switzerland) · 2025Review
- The Hepato-Cardio-Renal Axis in Cirrhosis: Hemodynamic and Mechanistic Insights, Diagnostic Biomarkers, and Expanding Therapeutic Horizons.Discoveries (Craiova, Romania)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
AKI is common in patients with liver cirrhosis (LC) affecting (30 to 50%). Our study aimed to evaluate the role of urinary biomarkers as predictors of AKI, its etiology and mortality. We performed a prospective cohort study of patients with LC during 1 year. Urine samples for biomarkers dosage were collected within 48 h of hospital admission. Diagnosis of AKI was performed according to KDIGO 2012 criteria. The results were presented using Chi-square, T test, AUC-ROC and logistic regression (p < 0.05). We included 100 patients, 58.5 ± 16.1 years, main etiologies of LC were alcohol and and metabolic disfunction associated with steatohepatitis. Infection was the main cause of LC decompensation. AKI occurred in 53% of patients and mortality was 20%. CHILD C, infectious as cause of decompensation, baseline creatinine, need for mechanical ventilation and noradrenaline use and urinary were associated with AKI. We found no association between AKI and KIM-1 and IL-18. The main etiologies of AKI were transient ischeamia (49%), renal (43.4%), and hepatorenal syndrome (HRS) (7.5%). There was difference between the groups in hematuria, proteinuria, FENa, FEUr and uNGAL which were higher in renal AKI when compared to transient ischaemia and HSR. FENa and FEUr were excellent predictors of AKI etiology (AUC-ROC > 0.80, sensitivity and specificity > 0.80), while only uNGAL was good predictor of AKI etiology (AUC-ROC, sensitivity and specificity > 0.70). Regarding death, CHILD C, baseline creatinine, KDIGO 3, septic AKI, need for mechanical ventilation and IL-18 were identified as associated variables. Only NGAL was predictor of AKI and its etiology, anticipating AKI diagnosis in 2.5 ± 1.1 days, while IL-18 was predictor of death. We highlight the importance of lower-cost biochemical tests as FENa and FEUr and clinical information as CHILD and cause of LC descompensation which were relevant in predicting AKI, its etiology and death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.